Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

LTRNBullishLegalnews

High materiality7/10

Patent allowance strengthens Lantern's LP-184 biomarker-guided precision oncology program.

Jul 23, 2026, 8:03 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Patent allowance adds durable IP moat; early efficacy signal (DCR 45%) and 2026 trial catalysts could drive re-rating, though no near-term FDA approval.

AI summary

What happened, with direct paths to the underlying reporting

Lantern Pharma received a USPTO Notice of Allowance for a three-gene signature (PTGR1, PTPN14, ASPH) guiding LP-184 use. In a 63-patient Phase 1a, 45% disease control was observed at the effective dose in 29 evaluable patients. The company plans 1b/2 trials in 2026, leveraging RADR AI to expand indications and attract partnerships.

USPTO Notice of Allowance covers a three-gene signature for LP-184.
63-patient Phase 1a showed 45% disease control at effective dose.
LP-184 to be evaluated in multiple Phase 1b/2 trials in 2026.
RADR AI platform aided biomarker identification and development.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.